Resistance to MAPK inhibitor induces internal duplication in BRAF
Ontology highlight
ABSTRACT: 2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation.
PROVIDER: EGAS00001001304 | EGA |
REPOSITORIES: EGA
ACCESS DATA